Photo Gallery

Login

Search

News & Updation

  • WJPPS OCTOBER ISSUE PUBLISHED
  • OCTOBER 2018 Issue has been successfully launched on 1 October 2018

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from 6.647 to 7.421 due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  

Abstract

FORMULATION AND EVALUATION OF GLIBENCLAMIDE CUBOSOMAL ORAL CAPSULES

Dr. S. Indira*, S. Dinesh Reddy and Dr. M. Bhagavan Raju

ABSTRACT

An attempt was made to investigate the potential of Cubosomes as lipid nanocarrier to improve the drug release action of the Glibenclamide. Glibenclamide Cubosomes were prepared by Top- Down approach employing GMO as lipid phase vehicle, Poloxamer- 407 as a stabiliser and distilled water as the aqueous phase. The resultant cubosomal dispersion was characterised by Encapsulation efficiency, in-vitro drug release, particle size, zeta potential, FTIR and SEM. Optimised Cubosomal formulation (G7) showed a maximum drug release of 83% in 7 hours, entrapment efficiency of 90%, the particle size of 110.3 nm and zeta potential of -41.3 mV. Glibenclamide Cubosomal oral capsules were prepared with optimised Cubosomal dispersion, by employing starch and Aerosil as granulating agents to obtain a wet mass. The wet mass is passed through the sieve no.16 to from granules and dried in hot air oven. The dried granules were filled into the capsules. The granules were evaluated for SEM, zeta potential, flow properties and Invitro drug release. Optimized Cubosomal capsule formulation (CG4) showed a maximum drug release of 51.17 % in 7 Hours, particle size of 2034.9 nm and Zeta potential of -27.6 mV. Invitro release kinetics exhibited the drug release up to 7 hours. Results suggest that GMO cubosomes, as lipid nanovectors in the form of Cubosomal Oral Capsules could significantly enhance the efficacy and sustain the release when compared to Glibenclamide Tablets (Daonil).

Keywords: Glibenclamide, GMO (Glyceryl Mono Oleate), Top-Down approach, Oral Capsules, Cubosomal Injection.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More